Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Growth From $6.4 Billion In 2026 To $8.41 Billion By 2030 At A CAGR Of 7.1%
The market for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) has experienced significant expansion lately, projected to advance from $5.97 billion in 2025 to $6.41 billion in 2026, reflecting a compound annual growth rate of 7.3%. Factors contributing to this historical growth trajectory include the restricted availability of specialized complement therapies, diagnostic delays stemming from the rarity of these conditions, a prevailing reliance on plasma exchange and supportive measures, elevated treatment expenses hindering accessibility, and a general lack of awareness regarding complement-mediated disorders.
The market for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) is poised for significant expansion in the coming years, projecting to reach $8.42 billion by 2030 with a compound annual growth rate of 7.1%. This anticipated growth is fueled by several key factors, including the creation of innovative complement inhibitors, enhanced diagnostic capabilities through sophisticated testing, a heightened emphasis on developing treatments for rare diseases, broader insurance coverage for these conditions, and the proliferation of specialized centers for hematology and nephrology. During this forecast period, prominent trends will encompass a greater acceptance of complement inhibitor treatments, increased utilization of genetic and biomarker analyses, the emergence of extended-release complement inhibition medications, the expansion of dedicated rare disease treatment facilities, and advancements in the early identification of complement-mediated conditions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24357&type=smp
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Growth Factors Supporting Long-Term Expansion
The expanding landscape of rare diseases is poised to stimulate considerable expansion within the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market. These rare conditions, by definition affecting a small segment of the populace, often fewer than 200,000 people, are frequently marked by their intricate nature, significant severity, and the necessity for specialized medical interventions. A key factor contributing to the heightened incidence of rare diseases is the progress in diagnostic methodologies, which facilitates superior detection and recognition of conditions that were formerly overlooked or remained unidentified. PNH and aHUS play a crucial role in advancing the comprehension and management of rare diseases, offering valuable perspectives on the underlying mechanisms and potential intervention points for illnesses that currently possess limited therapeutic avenues. To illustrate, as of November 2024, the U.S. Food and Drug Administration reported that over 7,000 distinct rare diseases affected more than 30 million individuals across the United States. Consequently, the increasing occurrence of rare diseases is acting as a significant catalyst for the growth trajectory of the PNH and aHUS market.
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Segment Breakdown: Which Categories Generate The Most Revenue?
The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market covered in this report is segmented –
1) By Type: Soliris, Ultomiris
2) By Disease Type: Paroxysmal Nocturnal Hemoglobinuria(PNH), Atypical Hemolytic Uremic Syndrome(aHUS)
3) By Treatment Type: Complement Inhibitors, Plasma Exchange Or Infusion, Other Symptomatic Treatments
4) By Diagnosis Method: Clinical Diagnosis, Genetic Testing, Biomarker Testing
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Soliris: Eculizumab For PNH, Eculizumab For aHUS, Eculizumab Biosimilars
2) By Ultomiris: Ravulizumab For PNH, Ravulizumab For aHUS, Ravulizumab Extended-Interval Dosing
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Industry Trends Shaping Future Revenue Growth
Within the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market, leading entities are actively pursuing the creation of novel therapeutic options, specifically complement inhibitors, aiming to enhance patient results and streamline treatment accessibility. Complement inhibitors function by impeding particular elements of the complement system, an immune network integral to removing infectious agents and compromised cells. As an illustration, in December of 2023, the U.S. Food and Drug Administration (FDA) granted approval to Fabhalta (iptacopan), developed by the Swiss pharmaceutical firm Novartis AG, marking it as the inaugural oral monotherapy designed for adult patients diagnosed with paroxysmal nocturnal hemoglobinuria; this treatment notably achieves superior hemoglobin stabilization, obviating the necessity for blood transfusions. This cutting-edge complement inhibitor exerts its effect by targeting and inhibiting Factor B within the alternative complement pathway, thereby affording thorough management of both intravascular and extravascular hemolytic processes. Furthermore, its convenient oral administration simplifies the complexities of managing the condition and elevates the overall quality of life for individuals affected by PNH, relieving them of the challenges inherent in regular intravenous infusions.
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Key Players And Strategic Industry Positioning
Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market are Roche Holding AG, Alexion Pharmaceuticals Inc, Genentech Inc, Novartis AG, Apellis Pharmaceuticals Inc, Omeros Corporation, BioCryst Pharmaceuticals Inc, ChemoCentryx Inc, Sanofi SA, CSL Behring, Takeda Pharmaceutical Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Horizon Therapeutics, Achillion Pharmaceuticals Inc, Sobi Swedish Orphan Biovitrum AB, ImmunoForge Co Ltd, Care Pharma, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, Mallinckrodt Pharmaceuticals, CANbridge Pharmaceuticals Inc.
Access The Complete Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Report:
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Regional Analysis And Leading Geography
North Americawas the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
